Significance of Myelin Oligodendrocyte Glycoprotein Antibodies in CSF: A Retrospective Multicenter Study.
Journal
Neurology
ISSN: 1526-632X
Titre abrégé: Neurology
Pays: United States
ID NLM: 0401060
Informations de publication
Date de publication:
14 03 2023
14 03 2023
Historique:
received:
27
03
2022
accepted:
24
10
2022
pubmed:
17
12
2022
medline:
16
3
2023
entrez:
16
12
2022
Statut:
ppublish
Résumé
Although the diagnosis of myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) is based on serum MOG antibodies (MOG-Abs) positivity, patients with coexisting or restricted MOG-Abs in the CSF have been reported. The aim of this study is to characterize the relevance of CSF MOG-Abs positivity in clinical practice. Eleven medical centers retrospectively collected clinical and laboratory data of adult and pediatric patients with suspected inflammatory CNS disease and MOG-Abs positivity in serum and/or CSF using live cell-based assays. Comparisons were performed using parametric or nonparametric tests, as appropriate. Potential factors of unfavorable outcomes were explored by Cox proportional hazard models and logistic regression. The cohort included 255 patients: 139 (55%) women and 132 (52%) children (i.e., <18-year-old). Among them, 145 patients (56.8%) had MOG-Abs in both serum and CSF (MOG-Abs seropositive and CSF positive), 79 (31%) only in serum (MOG-Abs seropositive and CSF negative), and 31 (12%) only in CSF (MOG-Abs seronegative and CSF positive). MOG-Abs seronegative and CSF positive predominated in adults (22% vs 3% of children), presented more commonly with motor (n = 14, 45%) and sensory symptoms (n = 13, 42%), and all but 4 (2 multiple sclerosis, 1 polyradiculoneuritis, and 1 Susac syndrome) had a final diagnosis compatible with MOGAD. When comparing seropositive patients according to MOG-Abs CSF status, MOG-Abs seropositive and CSF positive patients had a higher Expanded Disability Status Scale (EDSS) at nadir during the index event (median 4.5, interquartile range [IQR] 3.0-7.5 vs 3.0, IQR 2.0-6.8, Paired serum and CSF MOG-Abs positivity are common in MOGAD and are associated with a more severe clinical presentation. CSF-only MOG-Abs positivity can occur in patients with a phenotype suggestive of MOGAD and is associated with a worse outcome. Taken together, these data suggest a clinical interest in assessing CSF MOG-Abs in patients with a phenotype suggestive of MOGAD, regardless of the MOG-Abs serostatus.
Sections du résumé
BACKGROUND AND OBJECTIVES
Although the diagnosis of myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) is based on serum MOG antibodies (MOG-Abs) positivity, patients with coexisting or restricted MOG-Abs in the CSF have been reported. The aim of this study is to characterize the relevance of CSF MOG-Abs positivity in clinical practice.
METHODS
Eleven medical centers retrospectively collected clinical and laboratory data of adult and pediatric patients with suspected inflammatory CNS disease and MOG-Abs positivity in serum and/or CSF using live cell-based assays. Comparisons were performed using parametric or nonparametric tests, as appropriate. Potential factors of unfavorable outcomes were explored by Cox proportional hazard models and logistic regression.
RESULTS
The cohort included 255 patients: 139 (55%) women and 132 (52%) children (i.e., <18-year-old). Among them, 145 patients (56.8%) had MOG-Abs in both serum and CSF (MOG-Abs seropositive and CSF positive), 79 (31%) only in serum (MOG-Abs seropositive and CSF negative), and 31 (12%) only in CSF (MOG-Abs seronegative and CSF positive). MOG-Abs seronegative and CSF positive predominated in adults (22% vs 3% of children), presented more commonly with motor (n = 14, 45%) and sensory symptoms (n = 13, 42%), and all but 4 (2 multiple sclerosis, 1 polyradiculoneuritis, and 1 Susac syndrome) had a final diagnosis compatible with MOGAD. When comparing seropositive patients according to MOG-Abs CSF status, MOG-Abs seropositive and CSF positive patients had a higher Expanded Disability Status Scale (EDSS) at nadir during the index event (median 4.5, interquartile range [IQR] 3.0-7.5 vs 3.0, IQR 2.0-6.8,
DISCUSSION
Paired serum and CSF MOG-Abs positivity are common in MOGAD and are associated with a more severe clinical presentation. CSF-only MOG-Abs positivity can occur in patients with a phenotype suggestive of MOGAD and is associated with a worse outcome. Taken together, these data suggest a clinical interest in assessing CSF MOG-Abs in patients with a phenotype suggestive of MOGAD, regardless of the MOG-Abs serostatus.
Identifiants
pubmed: 36526426
pii: WNL.0000000000201662
doi: 10.1212/WNL.0000000000201662
pmc: PMC10074465
doi:
Substances chimiques
Myelin-Oligodendrocyte Glycoprotein
0
Aquaporin 4
0
Autoantibodies
0
Types de publication
Multicenter Study
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e1095-e1108Subventions
Organisme : NINDS NIH HHS
ID : R01 NS113828
Pays : United States
Commentaires et corrections
Type : CommentIn
Informations de copyright
© 2022 American Academy of Neurology.
Références
JAMA Neurol. 2018 Apr 1;75(4):478-487
pubmed: 29305608
Acta Neuropathol Commun. 2019 Sep 3;7(1):145
pubmed: 31481127
Neurology. 2019 Mar 12;92(11):e1250-e1255
pubmed: 30728305
Neurol Neuroimmunol Neuroinflamm. 2020 Feb 5;7(2):
pubmed: 32024795
Ann Clin Transl Neurol. 2017 May 09;4(6):369-380
pubmed: 28589164
J Neuroinflammation. 2016 Sep 26;13(1):279
pubmed: 27788675
Neurology. 2019 Nov 12;93(20):e1867-e1872
pubmed: 31645473
JAMA Neurol. 2020 Dec 1;77(12):1575-1577
pubmed: 32865549
JAMA Neurol. 2018 Nov 1;75(11):1355-1363
pubmed: 30014148
J Neuroinflammation. 2015 Jan 28;12:19
pubmed: 25626447
Neurol Neuroimmunol Neuroinflamm. 2020 Jan 3;7(2):
pubmed: 31900318
Acta Neuropathol. 2021 May;141(5):801-804
pubmed: 33609159
Brain. 2017 Dec 1;140(12):3128-3138
pubmed: 29136091
J Neuroinflammation. 2020 Sep 3;17(1):261
pubmed: 32883348
Ann Clin Transl Neurol. 2017 Oct 03;4(11):768-783
pubmed: 29159189
Invest Ophthalmol Vis Sci. 2001 Apr;42(5):895-901
pubmed: 11274064
Lancet Neurol. 2020 Mar;19(3):234-246
pubmed: 32057303
Neurol Neuroimmunol Neuroinflamm. 2020 May 1;7(4):
pubmed: 32358225
J Neurol Neurosurg Psychiatry. 2022 Mar;93(3):334-335
pubmed: 34261747
Ann Neurol. 2021 Jan;89(1):30-41
pubmed: 32959427
Ann Neurol. 2009 Dec;66(6):833-42
pubmed: 20033986
Lancet Neurol. 2018 Feb;17(2):162-173
pubmed: 29275977
Eur J Neurol. 2004 Aug;11(8):525-9
pubmed: 15272896
Neurol Neuroimmunol Neuroinflamm. 2017 Jan 16;4(2):e322
pubmed: 28105459
Neurol Neuroimmunol Neuroinflamm. 2021 Oct 28;9(1):
pubmed: 34711644
Curr Opin Neurol. 2019 Jun;32(3):459-466
pubmed: 30762607
Nat Rev Neurol. 2019 Feb;15(2):89-102
pubmed: 30559466
Neurol Neuroimmunol Neuroinflamm. 2021 Sep 17;8(6):
pubmed: 34535569
JAMA Neurol. 2016 Sep 1;73(9):1115-24
pubmed: 27428927
Neurology. 2018 May 22;90(21):e1858-e1869
pubmed: 29695592
JAMA Neurol. 2020 Jan 1;77(1):82-93
pubmed: 31545352
J Neurol. 2017 Dec;264(12):2420-2430
pubmed: 29063242
JAMA Neurol. 2021 Jun 1;78(6):741-746
pubmed: 33900394
Rev Neurol (Paris). 2021 Jan-Feb;177(1-2):39-50
pubmed: 33046261
Mult Scler J Exp Transl Clin. 2021 Jun 25;7(2):20552173211022767
pubmed: 34262784
Ann Neurol. 2018 Aug;84(2):315-328
pubmed: 30014603
J Neuroinflammation. 2018 May 3;15(1):134
pubmed: 29724224
Ther Adv Neurol Disord. 2012 May;5(3):147-59
pubmed: 22590479
Mult Scler. 2016 Dec;22(14):1821-1829
pubmed: 26869530
Lancet Neurol. 2008 Dec;7(12):1091-8
pubmed: 18851928
Nat Rev Neurosci. 2019 Dec;20(12):728-745
pubmed: 31712781
Crit Rev Clin Lab Sci. 2022 Sep;59(6):391-404
pubmed: 35277112
Neurology. 2021 Jul 6;97(1):e1-e12
pubmed: 33980704
Brain. 2007 Feb;130(Pt 2):514-20
pubmed: 17114796
Lancet Neurol. 2014 Feb;13(2):167-77
pubmed: 24360484
J Neurol. 2016 Jul;263(7):1349-60
pubmed: 27147513